Target type: biologicalprocess
The process in which a relatively unspecialized cell acquires the specialized features of a photoreceptor cell, as found in the eye, the primary visual organ of most organisms. [GOC:go_curators]
The development of photoreceptor cells in the eye is a complex and tightly regulated process that involves the coordinated expression of numerous genes and signaling pathways. Here's a breakdown of the key stages:
**1. Commitment and Specification:**
* **Multipotent Progenitor Cells:** The journey begins with multipotent progenitor cells in the developing retina, capable of becoming various retinal cell types, including photoreceptor cells.
* **Transcription Factors:** Crucial transcription factors, like Otx2 and Pax6, play a role in specifying the fate of these progenitors toward a photoreceptor lineage.
**2. Differentiation and Maturation:**
* **Rod and Cone Precursors:** Progenitor cells commit to either rod or cone photoreceptor cell fate, distinguished by their distinct light sensitivity and function.
* **Morphological Changes:** Cells undergo significant morphological changes, including the development of a specialized outer segment, where light detection occurs. This involves:
* **Outer Segment Formation:** The outer segment elongates, forming stacks of membranous discs, which house light-sensitive pigments like rhodopsin (in rods) or cone opsins (in cones).
* **Ciliary Bridge:** A specialized structure called the ciliary bridge connects the outer segment to the cell body, facilitating the transport of proteins and lipids.
* **Pigment Synthesis:** Photoreceptor cells begin synthesizing and assembling the necessary photopigments, rhodopsin or cone opsins, within the outer segment. These pigments are critical for light absorption and signal transduction.
* **Synaptic Connections:** Photoreceptor cells establish synaptic connections with downstream neurons, including bipolar and horizontal cells, in the inner retina. This forms the foundation for transmitting visual signals to the brain.
**3. Fine-Tuning and Maintenance:**
* **Fine-tuning of Sensitivity:** The number and arrangement of discs within the outer segment, as well as the expression of various proteins, contribute to the fine-tuning of light sensitivity in rods and cones.
* **Constant Renewal:** Photoreceptor cells have a unique characteristic of constantly shedding and renewing their outer segments, which helps maintain optimal light sensitivity. This process involves phagocytosis by retinal pigment epithelial (RPE) cells.
**4. Role of Signaling Pathways:**
* **Shh (Sonic Hedgehog) Pathway:** Shh signaling plays a crucial role in regulating the proliferation and differentiation of photoreceptor progenitors.
* **Wnt Pathway:** Wnt signaling is involved in the specification of photoreceptor cell fate and the formation of the outer segment.
* **TGF-β (Transforming Growth Factor beta) Pathway:** TGF-β signaling contributes to the development and maintenance of photoreceptor cell function.
**5. Regulation of Cell Death:**
* **Apoptosis:** During development and in some disease states, photoreceptor cells can undergo programmed cell death (apoptosis). This process is precisely regulated to ensure proper retinal development and homeostasis.
The development of functional photoreceptor cells is essential for our ability to perceive light and form visual images. This intricate process is precisely regulated by genetic programs and signaling pathways, ensuring the formation of the highly specialized cells that enable sight.'
"
Protein | Definition | Taxonomy |
---|---|---|
Signal transducer and activator of transcription 3 | A signal transducer and activator of transcription 3 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P40763] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
niclosamide | niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections. Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48) | benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide | anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor |
oleanolic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | plant metabolite | |
nitazoxanide | nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug | benzamides; carboxylic ester | |
loganin | beta-D-glucoside; cyclopentapyran; enoate ester; iridoid monoterpenoid; methyl ester; monosaccharide derivative; secondary alcohol | anti-inflammatory agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.4.23.46 (memapsin 2) inhibitor; neuroprotective agent; plant metabolite | |
tetrahydrocurcumin | tetrahydrocurcumin : A beta-diketone that is curcumin in which both of the double bonds have been reduced to single bonds. | beta-diketone; diarylheptanoid; polyphenol | metabolite |
cryptotanshinone | cryptotanshinone: from Salvia miltiorrhiza | abietane diterpenoid | anticoronaviral agent |
ar-turmerone | (+)-(S)-ar-turmerone : A sesquiterpenoid that is 2-methylhept-2-en-4-one substituted by a 4-methylphenyl group at position 6. It has been isolated from Peltophorum dasyrachis. ar-turmerone: potent antivenom against snake bites; isolated form Curcuma longa; structure given in first source | enone; sesquiterpenoid | EC 3.1.1.7 (acetylcholinesterase) inhibitor; plant metabolite |
sweroside | glycoside | ||
nsc 74859 | NSC 74859: inhibits Stat3 binding activity; structure in first source S3I-201 : An amidobenzoic acid obtained by formal condensation of the carboxy group of [(4-methylbenzene-1-sulfonyl)oxy]acetic acid with the amino group of 4-amino-2-hydroxybenzoic acid. | amidobenzoic acid; monohydroxybenzoic acid; tosylate ester | STAT3 inhibitor |
telocinobufagin | telocinobufagin: structure | steroid lactone | |
tizoxanide | tizoxanide: major metabolite of nitazoxanide; structure in first source | salicylamides | |
bardoxolone methyl | methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate: structure in first source | cyclohexenones | |
bisabolol | Kamillosan: drug combination containing chamomile and bisabolol; used to treat dermatitis | sesquiterpenoid | |
ganoderic acid a | triterpenoid | ||
piplartine | piplartine: Antineoplastic Agent, Phytogenic; alkaloid from Piper; structure in first source | cinnamamides; dicarboximide | |
stattic | 1-benzothiophenes; C-nitro compound; sulfone | antineoplastic agent; radiosensitizing agent; STAT3 inhibitor | |
stx-0119 | STX-0119: antineoplastic; structure in first source | ||
genistein | 7-hydroxyisoflavones | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor | |
andrographolide | carbobicyclic compound; gamma-lactone; labdane diterpenoid; primary alcohol; secondary alcohol | anti-HIV agent; anti-inflammatory drug; antineoplastic agent; metabolite | |
nifuroxazide | nifuroxazide: structure | benzoic acids | |
hylin | |||
2-acetylfuranonaphthoquinone | 2-acetylfuranonaphthoquinone: has antineoplastic activity; structure in first source | ||
5,15-diphenylporphine | 5,15-diphenylporphine: structure in first source | ||
wp1066 | |||
azd 1480 | |||
bp-1-102 | BP-1-102: a STAT3 inhibitor; structure in first source | ||
phaeosphaeride a | phaeosphaeride A: inhibits STAT3-dependent signaling; structure in first source | ||
hydrazinocurcumin | hydrazinocurcumin : A pyrazole obtained by cyclocodensation of the two carbonyl groups of curcumin with hydrazine. hydrazinocurcumin: structure in first source | aromatic ether; olefinic compound; polyphenol; pyrazoles | angiogenesis modulating agent; antineoplastic agent; EC 2.3.1.48 (histone acetyltransferase) inhibitor; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor |